TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II, Randomised, Placebo Controlled, Multicentre, Feasibility Study of Low Dose (Metronomic) Cyclophosphamide With and Without Nintedanib (BIBF 1120) in Advanced Ovarian Cancer
Brief Summary: The primary objective is to explore the efficacy and safety of an all oral combination of BIBF 1120 (an inhibitor of angiogenic signalling) and metronomic cyclophosphamide in patients with multiply-relapsed advanced ovarian cancer, who have completed a minimum of two lines of previous chemotherapy and who for any reason are not suitable for further 'standard' intravenous chemotherapy treatments.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SPARC147609 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Reference147609 | Intervention Type: DRUG; Name: SPARC147609; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Reference147609; Assigned to Arm(s): 2
B: Arm Label: Ovarian cancer; Type: EXPERIMENTAL; Interventions: Drug: Oral rucaparib | Intervention Type: DRUG; Name: Oral rucaparib; Assigned to Arm(s): Ovarian cancer
C: Arm Label: Cyclophosphamide and BIBF-1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120 | Arm Label: Cyclophosphamide and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIBF 1120 | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): Cyclophosphamide and BIBF-1120, Cyclophosphamide and placebo
D: Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: study of socioeconomic and demographic variables; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II, Randomised, Placebo Controlled, Multicentre, Feasibility Study of Low Dose (Metronomic) Cyclophosphamide With and Without Nintedanib (BIBF 1120) in Advanced Ovarian Cancer
Brief Summary: The primary objective is to explore the efficacy and safety of an all oral combination of BIBF 1120 (an inhibitor of angiogenic signalling) and metronomic cyclophosphamide in patients with multiply-relapsed advanced ovarian cancer, who have completed a minimum of two lines of previous chemotherapy and who for any reason are not suitable for further 'standard' intravenous chemotherapy treatments.


Options:
A: Arm Label: Rucaparib; Type: EXPERIMENTAL; Interventions: Drug: Rucaparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rucaparib; Assigned to Arm(s): Rucaparib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Placebo olaparib, Drug: Durvalumab placebo, Drug: Carboplatin+Paclitaxel | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Durvalumab, Drug: Placebo olaparib, Drug: Carboplatin+Paclitaxel | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Durvalumab, Drug: Olaparib, Drug: Carboplatin+Paclitaxel | Arm Label: tBRCAm cohort; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Durvalumab, Drug: Olaparib, Drug: Carboplatin+Paclitaxel | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm 1, Arm 2, Arm 3, tBRCAm cohort | Intervention Type: DRUG; Name: Durvalumab; Assigned to Arm(s): Arm 2, Arm 3, tBRCAm cohort | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Arm 3, tBRCAm cohort | Intervention Type: DRUG; Name: Placebo olaparib; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: Durvalumab placebo; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Carboplatin+Paclitaxel; Assigned to Arm(s): Arm 1, Arm 2, Arm 3, tBRCAm cohort
C: Arm Label: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Cyclophosphamide and BIBF-1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120 | Arm Label: Cyclophosphamide and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIBF 1120 | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): Cyclophosphamide and BIBF-1120, Cyclophosphamide and placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Brief Summary: The purpose of this study is to examine the safety and efficacy of Ibrutinib administered in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).


Options:
A: Arm Label: Ibrutinib + BR; Type: EXPERIMENTAL; Interventions: Drug: Ibrutinib, Drug: Bendamustine hydrochloride, Drug: Rituximab | Arm Label: Placebo + BR; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bendamustine hydrochloride, Drug: Rituximab, Drug: Placebo | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Ibrutinib + BR | Intervention Type: DRUG; Name: Bendamustine hydrochloride; Assigned to Arm(s): Ibrutinib + BR, Placebo + BR | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Ibrutinib + BR, Placebo + BR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + BR
B: Intervention Type: DRUG; Name: HuMax-CD20; Assigned to Arm(s): N/A
C: Arm Label: Ofatumumab; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab | Arm Label: Physicians' Choice; Type: ACTIVE_COMPARATOR; Interventions: Drug: Physicians' Choice | Intervention Type: DRUG; Name: Ofatumumab; Assigned to Arm(s): Ofatumumab | Intervention Type: DRUG; Name: Physicians' Choice; Assigned to Arm(s): Physicians' Choice
D: Arm Label: Bendamustine + GA101 + CAL-101; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: GA101, Drug: CAL-101 | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Bendamustine + GA101 + CAL-101 | Intervention Type: DRUG; Name: GA101; Assigned to Arm(s): Bendamustine + GA101 + CAL-101 | Intervention Type: DRUG; Name: CAL-101; Assigned to Arm(s): Bendamustine + GA101 + CAL-101

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Randomized, Placebo-controlled, Double Blind Study of Venlafaxine to Prevent Oxaliplatin-Induced Neuropathy
Brief Summary: You are being asked to take part in this research study because you are going to be treated with oxaliplatin chemotherapy as part of your standard care. Oxaliplatin commonly causes neuropathy (numbing, tingling and/or pain).The purpose of this study is to compare the effects, good and/or bad, of venlafaxine with a placebo (an inactive agent) on oxaliplatin-induced neuropathy (numbing, tingling and/or pain)


Options:
A: Arm Label: Arm I (management of therapy complications); Type: EXPERIMENTAL; Interventions: Drug: venlafaxine, Other: questionnaire administration, Other: quality-of-life assessment | Arm Label: Arm II (placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Other: questionnaire administration, Other: quality-of-life assessment | Intervention Type: DRUG; Name: venlafaxine; Assigned to Arm(s): Arm I (management of therapy complications) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Arm II (placebo) | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): Arm I (management of therapy complications), Arm II (placebo) | Intervention Type: OTHER; Name: quality-of-life assessment; Assigned to Arm(s): Arm I (management of therapy complications), Arm II (placebo)
B: Arm Label: Psilocybin; Type: EXPERIMENTAL; Interventions: Drug: Psilocybin, Drug: Niacin | Arm Label: Niacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Psilocybin, Drug: Niacin | Intervention Type: DRUG; Name: Psilocybin; Assigned to Arm(s): Niacin, Psilocybin | Intervention Type: DRUG; Name: Niacin; Assigned to Arm(s): Niacin, Psilocybin
C: Arm Label: Low Dose First, High Dose Second; Type: EXPERIMENTAL; Interventions: Drug: psilocybin | Arm Label: High Dose First, Low Dose Second; Type: EXPERIMENTAL; Interventions: Drug: psilocybin | Intervention Type: DRUG; Name: psilocybin; Assigned to Arm(s): High Dose First, Low Dose Second, Low Dose First, High Dose Second
D: Arm Label: Arm I - Placebo; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Placebo Powder, Drug: Placebo Pill | Arm Label: Arm II - Soy; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: oral soy protein/isoflavones powder, Drug: Placebo Pill | Arm Label: Arm III - Venlafaxine; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine, Dietary Supplement: Placebo Powder | Arm Label: Arm IV - Soy + Venlafaxine; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: oral soy protein/isoflavones powder, Drug: Venlafaxine | Intervention Type: DIETARY_SUPPLEMENT; Name: oral soy protein/isoflavones powder; Assigned to Arm(s): Arm II - Soy, Arm IV - Soy + Venlafaxine | Intervention Type: DRUG; Name: Venlafaxine; Assigned to Arm(s): Arm III - Venlafaxine, Arm IV - Soy + Venlafaxine | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo Powder; Assigned to Arm(s): Arm I - Placebo, Arm III - Venlafaxine | Intervention Type: DRUG; Name: Placebo Pill; Assigned to Arm(s): Arm I - Placebo, Arm II - Soy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Randomized, Placebo-controlled, Double Blind Study of Venlafaxine to Prevent Oxaliplatin-Induced Neuropathy
Brief Summary: You are being asked to take part in this research study because you are going to be treated with oxaliplatin chemotherapy as part of your standard care. Oxaliplatin commonly causes neuropathy (numbing, tingling and/or pain).The purpose of this study is to compare the effects, good and/or bad, of venlafaxine with a placebo (an inactive agent) on oxaliplatin-induced neuropathy (numbing, tingling and/or pain)


Options:
A: Arm Label: quetiapine; Type: EXPERIMENTAL; Interventions: Drug: quetiapine | Arm Label: escitalopram; Type: ACTIVE_COMPARATOR; Interventions: Drug: escitalopram | Intervention Type: DRUG; Name: quetiapine; Assigned to Arm(s): quetiapine | Intervention Type: DRUG; Name: escitalopram; Assigned to Arm(s): escitalopram
B: Arm Label: Desipramine HCl; Type: EXPERIMENTAL; Interventions: Drug: Desipramine HCL | Intervention Type: DRUG; Name: Desipramine HCL; Assigned to Arm(s): Desipramine HCl
C: Arm Label: Arm I - Placebo; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Placebo Powder, Drug: Placebo Pill | Arm Label: Arm II - Soy; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: oral soy protein/isoflavones powder, Drug: Placebo Pill | Arm Label: Arm III - Venlafaxine; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine, Dietary Supplement: Placebo Powder | Arm Label: Arm IV - Soy + Venlafaxine; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: oral soy protein/isoflavones powder, Drug: Venlafaxine | Intervention Type: DIETARY_SUPPLEMENT; Name: oral soy protein/isoflavones powder; Assigned to Arm(s): Arm II - Soy, Arm IV - Soy + Venlafaxine | Intervention Type: DRUG; Name: Venlafaxine; Assigned to Arm(s): Arm III - Venlafaxine, Arm IV - Soy + Venlafaxine | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo Powder; Assigned to Arm(s): Arm I - Placebo, Arm III - Venlafaxine | Intervention Type: DRUG; Name: Placebo Pill; Assigned to Arm(s): Arm I - Placebo, Arm II - Soy
D: Arm Label: Arm I (management of therapy complications); Type: EXPERIMENTAL; Interventions: Drug: venlafaxine, Other: questionnaire administration, Other: quality-of-life assessment | Arm Label: Arm II (placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Other: questionnaire administration, Other: quality-of-life assessment | Intervention Type: DRUG; Name: venlafaxine; Assigned to Arm(s): Arm I (management of therapy complications) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Arm II (placebo) | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): Arm I (management of therapy complications), Arm II (placebo) | Intervention Type: OTHER; Name: quality-of-life assessment; Assigned to Arm(s): Arm I (management of therapy complications), Arm II (placebo)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Redesigning Medication Intensification Effectiveness Study for Diabetes
Brief Summary: The proposed research study aims to determine whether applying the University of Pittsburgh Medical Center Nurse-Directed Diabetes Management Protocols (NDMPs) leads to improved clinical outcome and process measures as recommended by American Diabetes Association (ADA), quality of life, treatment satisfaction and medication adherence for adults with diabetes, and favorable providers' satisfaction as compared to usual diabetes care. Furthermore, the cost-effectiveness of performing the NDMPs compared to usual diabetes care in primary care settings will also be assessed.


Options:
A: Arm Label: Group Clinic; Type: EXPERIMENTAL; Interventions: Behavioral: Improving outcomes using group clinics for older patients | Arm Label: Uusual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Standard of Care | Intervention Type: BEHAVIORAL; Name: Improving outcomes using group clinics for older patients; Assigned to Arm(s): Group Clinic | Intervention Type: BEHAVIORAL; Name: Standard of Care; Assigned to Arm(s): Uusual Care
B: Arm Label: Early Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: ALL | Arm Label: Late implementation; Type: ACTIVE_COMPARATOR; Interventions: Other: ALL | Intervention Type: OTHER; Name: ALL; Assigned to Arm(s): Early Intervention | Intervention Type: OTHER; Name: ALL; Assigned to Arm(s): Late implementation
C: Arm Label: Diabetes Educational Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Education | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Diabetes Education; Assigned to Arm(s): Diabetes Educational Intervention
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group, treatment algorithms; Type: EXPERIMENTAL; Interventions: Other: Treatment Algorithms | Intervention Type: OTHER; Name: Treatment Algorithms; Assigned to Arm(s): Intervention Group, treatment algorithms

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimal Timing of Foley Catheter Removal in Patients Undergoing Thoracic Surgery With Epidural Analgesia: A Randomized, Controlled Trial
Brief Summary: Is the early removal of Foley catheter safe in patients undergoing general thoracic surgery with an epidural catheter in place?


Options:
A: Arm Label: Early (within 48 hours of surgery); Type: N/A; Interventions: N/A | Arm Label: Late (6 hours after epidural removal); Type: N/A; Interventions: N/A
B: Arm Label: Immediate catheter removal; Type: EXPERIMENTAL; Interventions: Procedure: Immediate catheter removal | Arm Label: Post op day 1 catheter removal; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Post op day 1 catheter removal | Intervention Type: PROCEDURE; Name: Immediate catheter removal; Assigned to Arm(s): Immediate catheter removal | Intervention Type: PROCEDURE; Name: Post op day 1 catheter removal; Assigned to Arm(s): Post op day 1 catheter removal
C: Arm Label: 24 hour postop catheter removal; Type: EXPERIMENTAL; Interventions: Drug: Prazosin given 6 hours prior to catheter removal in the 24 hour group | Arm Label: 72 hour postoperative catheter removal; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Prazosin given 6 hours prior to catheter removal in the 24 hour group; Assigned to Arm(s): 24 hour postop catheter removal
D: Arm Label: voiding trial 4 hours post-op; Type: EXPERIMENTAL; Interventions: Procedure: Retrograde voiding trial | Arm Label: voiding trial post-op day 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Retrograde voiding trial | Intervention Type: PROCEDURE; Name: Retrograde voiding trial; Assigned to Arm(s): voiding trial 4 hours post-op, voiding trial post-op day 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Profilo Degli Acidi Grassi Omega-3 Dei Globuli Rossi in Neonati Sani Alimentati Con Una Formula Per l'Infanzia Contenente Una Miscela di Grassi Del Latte e Oli Vegetali
Brief Summary: The objective of this study is to determine whether the use of a mix of dairy lipids and plant oils in infant formula can increase the sum of omega-3 fatty acids levels in membrane phospholipids of red blood cells (RBC) in 4 month-old infants compared with a formula containing only lipids of plant origin.


Options:
A: Arm Label: Marinol; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Marinol D-40 | Arm Label: Nutrition counseling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Marinol D-40; Assigned to Arm(s): Marinol
B: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: MicroLipid and fish oil | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Routine care | Intervention Type: DIETARY_SUPPLEMENT; Name: MicroLipid and fish oil; Assigned to Arm(s): Treatment | Intervention Type: OTHER; Name: Routine care; Assigned to Arm(s): Control Group
C: Arm Label: Dairy lipids and plant oils; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Formula containing dairy lipids and plant oils | Arm Label: Plant oils; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Formula containing plant oils | Arm Label: Dairy lipids and plant oils, DHA+ARA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Formula containing dairy lipids and plant oils, DHA+ARA | Arm Label: Human milk; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Formula containing dairy lipids and plant oils; Assigned to Arm(s): Dairy lipids and plant oils | Intervention Type: DIETARY_SUPPLEMENT; Name: Formula containing plant oils; Assigned to Arm(s): Plant oils | Intervention Type: DIETARY_SUPPLEMENT; Name: Formula containing dairy lipids and plant oils, DHA+ARA; Assigned to Arm(s): Dairy lipids and plant oils, DHA+ARA
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: DHA and ARA | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: DHA and ARA | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Other: DHA and ARA | Arm Label: 4; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: DHA and ARA; Assigned to Arm(s): 1, 2, 3 | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): 4

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The objective of the study is to analyze the effectiveness and the cost-effectiveness of telecoching in improving glyceamic control and other modifiable risk factors in patients with type 2 diabetes compared to usual care only.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Procedure: Web-based care management | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Telephone and face-to-face care management | Arm Label: Arm 3; Type: SHAM_COMPARATOR; Interventions: Procedure: Internet access alone | Intervention Type: PROCEDURE; Name: Web-based care management; Assigned to Arm(s): Arm 1 | Intervention Type: PROCEDURE; Name: Telephone and face-to-face care management; Assigned to Arm(s): Arm 2 | Intervention Type: PROCEDURE; Name: Internet access alone; Assigned to Arm(s): Arm 3
B: Arm Label: telecoaching; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: telecoaching | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: telecoaching; Assigned to Arm(s): telecoaching
C: Arm Label: Family plus community focused intervention; Type: EXPERIMENTAL; Interventions: Behavioral: PILI 'Ohana Lifestyle Program | Arm Label: Standard Behavioral Weight Loss Maintenance Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Behavioral Weight Loss Maintenance Program | Intervention Type: BEHAVIORAL; Name: PILI 'Ohana Lifestyle Program; Assigned to Arm(s): Family plus community focused intervention | Intervention Type: BEHAVIORAL; Name: Standard Behavioral Weight Loss Maintenance Program; Assigned to Arm(s): Standard Behavioral Weight Loss Maintenance Intervention
D: Intervention Type: BEHAVIORAL; Name: An individual motivational intervention program to promote and maintain self-care behaviour; Assigned to Arm(s): N/A

Answer: B